CSCS

Parker University Announces the Accreditation of its Master of Science in Strength and Human Performance Program

Retrieved on: 
Monday, March 25, 2024
Health, Metabolism, Conditioning, CSC, Physiology, Education, Knowledge, Accreditation, Research, Faculty, Athlete, Student, Council, American College, CSCS, Curriculum, Lung compliance, Power, NSCA, ARC, Parker University, Sports medicine, Rehabilitation, Nursing

Parker University is proud to announce that its graduate-level Strength and Conditioning program has been granted five years of initial accreditation status!

Key Points: 
  • Parker University is proud to announce that its graduate-level Strength and Conditioning program has been granted five years of initial accreditation status!
  • Parker University’s Strength and Human Performance Program Director Jenna Romanelli, MS, Med, RD, CSC, says, “The CASCE accreditation directly reflects our Strength and Human Performance degree.
  • Parker University’s degrees in Strength and Human Performance provide students with an expansive study of evidence-based research in physiology, biomechanics, and human metabolism to enhance health, function, and physical performance.
  • Parker University is proud of its unwavering dedication to providing strength and conditioning education of the highest quality.

Karen E. Todd, VP Global Marketing of Kyowa Hakki U.S.A. Named MM+M 2024 WOMEN OF DISTINCTION Honoree

Retrieved on: 
Tuesday, April 2, 2024
Health, Organization, CSCS

NEW YORK, April 2, 2024 /PRNewswire-PRWeb/ -- Kyowa Hakko U.S.A., Inc., is delighted to announce that Karen E. Todd, RD, CSCS, EP-C, CISSN, and Vice President of Global Brand Marketing, has been named an MM+M 2024 Women of Distinction honoree. The 2024 Women of Distinction and Women to Watch honorees will celebrate 55 established and up-and-coming leaders at an in-person event on June 13 in New York City.

Key Points: 
  • NEW YORK, April 2, 2024 /PRNewswire-PRWeb/ -- Kyowa Hakko U.S.A., Inc., is delighted to announce that Karen E. Todd, RD, CSCS, EP-C, CISSN, and Vice President of Global Brand Marketing, has been named an MM+M 2024 Women of Distinction honoree.
  • The 2024 Women of Distinction and Women to Watch honorees will celebrate 55 established and up-and-coming leaders at an in-person event on June 13 in New York City.
  • The MM+M Women of Distinction and Women to Watch programs celebrate healthcare marketing executives who have significantly impacted their organizations during the past year.
  • "It's thrilling to have been named a Women of Distinction honoree.

Therabody Expands Investment in Science with $10 Million Research Pledge, Scientific Partnerships and Official Scientific Advisory Board

Retrieved on: 
Tuesday, March 12, 2024
Exercise, Learning, Men's Health, Beauty, MSHS, Sports medicine, Hot, NFL, Physical, Research, Innovation, The New York Times, The Pew Charitable Trusts, Partnership, Private practice, Education, Harvard University, Mexico national football team, Policy, Bodybuilding.com, MLS, American College, Physical fitness, Medicine, Fatigue, Harvard Medical School, Metabolism, Longevity, Advisory board, Sport, Public, FACP, ACSM, Senior, Athlete, MPH, FACSM, LOS, DPT, Premiership Rugby, Physical activity, Doctor of Philosophy, Physical therapy, Quicksilver, CSCS, MLB, Johns Hopkins University, Red Bull, Osteoporosis, Bangladesh Technical Education Board, NBA, Physician

LOS ANGELES, March 12, 2024 /PRNewswire/ -- Therabody, the leader in wellness technology, announced today the investment of more than $10M to fund initiatives that will continue to drive innovation and the scientific validation of their products. The company also announced the formalization of their Scientific Advisory Board and, significantly, a partnership with the American College of Sports Medicine (ACSM), the global research leader in the field of exercise, physical fitness and sports medicine.

Key Points: 
  • In an evolving regulatory landscape, Therabody believes that science is essential for leading the way forward as technology will transform healthcare over the next decade.
  • Their $10 million investment in scientific research will drive an integrated strategy for scientific leadership in the industry with funds put toward scientific and clinical research studies across beauty, wellness and athletic performance over the next several years.
  • Our Scientific Advisory Board, along with our significant investment in scientific research and partnerships, will ensure we remain at the forefront of our industry and dedicated to developing the most effective, scientifically validated products available today and in the future," said Monty Sharma, President and CEO of Therabody.
  • Therabody has completed 21 scientific studies to date with 26 currently in progress.

Therabody Expands Investment in Science with $10 Million Research Pledge, Scientific Partnerships and Official Scientific Advisory Board

Retrieved on: 
Tuesday, March 12, 2024
Exercise, Learning, Men's Health, Beauty, MSHS, Sports medicine, Hot, NFL, Physical, Research, Innovation, The New York Times, The Pew Charitable Trusts, Partnership, Private practice, Education, Harvard University, Mexico national football team, Policy, Bodybuilding.com, MLS, American College, Physical fitness, Medicine, Fatigue, Harvard Medical School, Metabolism, Longevity, Advisory board, Sport, Public, FACP, ACSM, Senior, Athlete, MPH, FACSM, LOS, DPT, Premiership Rugby, Physical activity, Doctor of Philosophy, Physical therapy, Quicksilver, CSCS, MLB, Johns Hopkins University, Red Bull, Osteoporosis, Bangladesh Technical Education Board, NBA, Physician

LOS ANGELES, March 12, 2024 /PRNewswire/ -- Therabody, the leader in wellness technology, announced today the investment of more than $10M to fund initiatives that will continue to drive innovation and the scientific validation of their products. The company also announced the formalization of their Scientific Advisory Board and, significantly, a partnership with the American College of Sports Medicine (ACSM), the global research leader in the field of exercise, physical fitness and sports medicine.

Key Points: 
  • In an evolving regulatory landscape, Therabody believes that science is essential for leading the way forward as technology will transform healthcare over the next decade.
  • Their $10 million investment in scientific research will drive an integrated strategy for scientific leadership in the industry with funds put toward scientific and clinical research studies across beauty, wellness and athletic performance over the next several years.
  • Our Scientific Advisory Board, along with our significant investment in scientific research and partnerships, will ensure we remain at the forefront of our industry and dedicated to developing the most effective, scientifically validated products available today and in the future," said Monty Sharma, President and CEO of Therabody.
  • Therabody has completed 21 scientific studies to date with 26 currently in progress.

Honey Stinger Expands NIL Program with Launch of National Campaign Featuring More Than 40 Athletes from Top NCAA Programs

Retrieved on: 
Monday, March 11, 2024
Honey, TBG, Sport, NCAA, Partnership, School, Gel, Female, Athlete, Male, CSCS, Ohio State University, NIL

STEAMBOAT SPRINGS, Colo., March 11, 2024 /PRNewswire-PRWeb/ -- Honey Stinger , a leading and most trusted sports nutrition brand, announces a significant expansion of its Name, Image, and Likeness (NIL) Program with the launch of a national campaign featuring more than 40 athletes from prominent NCAA programs.

Key Points: 
  • STEAMBOAT SPRINGS, Colo., March 11, 2024 /PRNewswire-PRWeb/ -- Honey Stinger , a leading and most trusted sports nutrition brand, announces a significant expansion of its Name, Image, and Likeness (NIL) Program with the launch of a national campaign featuring more than 40 athletes from prominent NCAA programs.
  • Honey Stinger has been a staple in college athletics, trusted by over 1,500 individual college and professional sports teams.
  • This campaign underscores our dedication to helping athletes achieve their goals and highlights our deep connection to collegiate sports.
  • This initiative reflects Honey Stinger's commitment to supporting athletes and promoting inclusivity within its NIL program.

Life Fitness Delivers on the Future of Fitness, Debuting State-of-the-Art Cardio Line with Next-Gen Biomechanics, Symbio™, at IHRSA 2024

Retrieved on: 
Tuesday, March 5, 2024
Acquisition, Los Angeles Convention Center, Sony, CSCS, Digital Solutions, Sprint, Connect, VO2, Peter Hancock (professor), Booth, Exercise, Life Fitness, Risk, Health, Athlete, Research, Nightclub

Life Fitness' latest innovations builds on the company's 55-year legacy as a cornerstone in gyms and fitness facilities around the world.

Key Points: 
  • Life Fitness' latest innovations builds on the company's 55-year legacy as a cornerstone in gyms and fitness facilities around the world.
  • Notably, the first-of-its-kind ultra-premium cardio line, Symbio™, will debut at IHRSA 2024, following the company's announcement of the four-machine collection in November 2023.
  • Life Fitness Debuts State-of-the-Art Cardio Line with Next-Gen Biomechanics, Symbio™, at IHRSA 2024
    The Symbio product series fuses advanced biomechanics, luxurious yet purposeful design, and personalized, immersive experiences to create the ultimate multi-sensory fitness experience.
  • "It's long been the aim of Life Fitness to bring new energy to the cardio space," said Dan Wille, Chief Product Officer, Life Fitness.

Life Fitness Delivers on the Future of Fitness, Debuting State-of-the-Art Cardio Line with Next-Gen Biomechanics, Symbio™, at IHRSA 2024

Retrieved on: 
Tuesday, March 5, 2024
Acquisition, Los Angeles Convention Center, Sony, CSCS, Digital Solutions, Sprint, Connect, VO2, Peter Hancock (professor), Booth, Exercise, Life Fitness, Risk, Health, Athlete, Research, Nightclub

Life Fitness' latest innovations builds on the company's 55-year legacy as a cornerstone in gyms and fitness facilities around the world.

Key Points: 
  • Life Fitness' latest innovations builds on the company's 55-year legacy as a cornerstone in gyms and fitness facilities around the world.
  • Notably, the first-of-its-kind ultra-premium cardio line, Symbio™, will debut at IHRSA 2024, following the company's announcement of the four-machine collection in November 2023.
  • "It's long been the aim of Life Fitness to bring new energy to the cardio space," said Dan Wille, Chief Product Officer, Life Fitness.
  • For more information about this Life Fitness' presence at IHRSA 2024 please contact:

Vista Physical Therapy Opens New Outpatient Clinic in Denton

Retrieved on: 
Wednesday, February 7, 2024
Partnership, Concussion, University, OCS, News, Sports medicine, Patient, University of North Texas, Vista, PRN, Love, Duell, Medical City Dallas Hospital, Vitis, Elective surgery, CSCS, DPT, Health, Insurance, Dry needling

Frisco, Texas, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vista Physical Therapy , a partner of Physical Rehabilitation Network (PRN) , has announced the grand opening of its third outpatient clinic in Denton, in collaboration with its joint venture partnership with Medical City Healthcare .

Key Points: 
  • Frisco, Texas, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vista Physical Therapy , a partner of Physical Rehabilitation Network (PRN) , has announced the grand opening of its third outpatient clinic in Denton, in collaboration with its joint venture partnership with Medical City Healthcare .
  • The Vista-Denton clinic offers comprehensive physical therapy services to patients of all ages, encompassing a diverse range of specialties.
  • Vista Physical Therapy’s Denton clinic proudly accepts most insurance plans and will work with patients to help them better understand the benefits of physical therapy and what will be covered by their insurance.
  • To schedule an appointment at the new Denton clinic, please visit the Vista Physical Therapy website .

Empower Physical Therapy Adds 4 Southern California Locations

Retrieved on: 
Monday, January 22, 2024
General Health, Sports, Health, Physical Therapy, General Sports, Patient, Physical, Private practice, DPT, Patient satisfaction, Rest, TMJD, CSCS, Mission Viejo, California, Acquisition, OC, OCS, Empower, ATC, Nursing

Empower Physical Therapy today announced the acquisition of Huntington Beach Physical Therapy Specialists (“HBPTS”), located in Orange County California.

Key Points: 
  • Empower Physical Therapy today announced the acquisition of Huntington Beach Physical Therapy Specialists (“HBPTS”), located in Orange County California.
  • Huntington Beach Physical Therapy Specialists have provided outpatient physical therapy services using a hands-on, individualized approach for over 25 years.
  • “Huntington Beach Physical Therapy Specialists, Tustin PT Specialists, and OrthoSport OC Physical Therapy have an outstanding reputation for providing access to exceptional care in the Orange County community which makes the team an incredible addition to the Empower Physical Therapy family,” said Empower Physical Therapy CEO & Physical Therapist Steve DiPaola.
  • Therapist-founded and -led Empower Physical Therapy owns and operates clinics across Arizona, California, Louisiana, and Texas.

Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office

Retrieved on: 
Tuesday, January 16, 2024
Research, Other Health, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, PPCB, OTC Markets Group, Patient, EFPIA, IP, PRP, Propane, Invention, CSCS, Cancer, Quality of life, Recurrence, Patent, United States of Europe, News, Statista, Pharmaceutical industry

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a certificate of grant for the Company’s foundation patent was received from the Canadian Intellectual Property Office.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a certificate of grant for the Company’s foundation patent was received from the Canadian Intellectual Property Office.
  • The foundation patent covers composition claims for the Company’s lead product candidate, PRP.
  • The Canadian foundation patent is the final application to receive a certificate of grant in the Company’s foundation patent family (there are two divisional patents remaining citing additional inventions in the US and Mexico further dividing an original patent,).
  • This means that grant status has been secured in every jurisdiction in which the Company has filed a foundation patent application.